Moderna, Inc. (MRNA) Stock: Surge as Phase 1 Ebola Vaccine Begins in Canada

TLDR

1. Moderna starts Phase 1 human testing of its Bundibugyo Ebola vaccine in Canada.
2. The trial will assess safety and immune response in about 80 healthy adults.
3. CEPI commits up to $50 million to support development and clinical trial supply.
4. No approved vaccine currently protects people against Bundibugyo Ebola disease.
5. Moderna pledges at least 500,000 doses for affected lower-income countries.

Moderna (MRNA) rose 4.37% to $57.55 after launching human testing for its Bundibugyo Ebola vaccine candidate in Canada. The company vaccinated the first participants after Health Canada authorized the Phase 1 study. The trial advances a vaccine program targeting an Ebola strain without an approved preventive option.

Moderna, Inc., MRNA

Moderna Begins First Human Trial for mRNA-1469

Moderna started the study at three Canadian sites using its mRNA-1469 vaccine candidate. Researchers will assess safety, tolerability, and immune responses among healthy adults. The trial plans to enroll about 80 participants during the first stage.

… Continue reading the full article at the original source below.